Present‐day clinical decisions for ER‐positive patients rely on the clinically used tumor characteristics including the breast cancer markers: PR, human epidermal growth factor receptor 2 (HER2), and proliferation marker Ki‐67. This evidence concerns the gene ESR1 and breast cancer.